Safety and Efficacy of Inhaled Treprostinil in Patients With PAH
NCT01557647 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL
Last updated 2012-03-26
Summary
To evaluate the effect of inhaled treprostinil compared to placebo on exercise capacity and time to clinical worsening.
Conditions
Interventions
- DRUG
-
Inhaled treprostinil
0.6mg/mL treprostinil for inhalation solution. Titrated up to 12 breaths QID.
- DRUG
-
placebo inhalation solution
Sponsors & Collaborators
-
United Therapeutics
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-06-30
- Primary Completion
- 2015-12-31
- Completion
- 2016-06-30
More Related Trials
-
A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension
NCT05564637 ·Status: COMPLETED ·Phase: PHASE2
-
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
NCT01560624 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)
NCT00147199 ·Status: COMPLETED ·Phase: PHASE3
-
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
NCT00705133 ·Status: COMPLETED ·Phase: PHASE2
-
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
NCT03794583 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07179380 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
NCT05176951 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
NCT02630316 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of Treprostinil in Intermediate-Risk Pulmonary Arterial Hypertension
NCT07177703 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)
NCT04791514 ·Status: TERMINATED ·Phase: PHASE2
-
Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects
NCT00741819 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
NCT02725372 ·Status: TERMINATED ·Phase: PHASE3
-
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
NCT05649748 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin
NCT00373360 ·Status: COMPLETED ·Phase: PHASE4
-
Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
NCT02276872 ·Status: COMPLETED ·Phase: PHASE2
-
An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT06939647 ·Status: AVAILABLE
-
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT05649722 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
NCT01560637 ·Status: COMPLETED ·Phase: PHASE3
-
FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
NCT00760916 ·Status: WITHDRAWN ·Phase: PHASE3
-
FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
NCT00325403 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)
NCT03055234 ·Status: WITHDRAWN ·Phase: PHASE3
-
Effects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension
NCT07116681 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
NCT02603068 ·Status: WITHDRAWN ·Phase: PHASE2
-
An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension
NCT01027949 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07234032 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3